Optiscan has received ethical clearance from the Royal Melbourne Hospital Human Research Ethics Committee to commence an in vivo clinical study focused on breast cancer. This significant milestone will enable us to demonstrate the capabilities of our recently unveiled InVue™ precision surgery imaging platform.

The study will evaluate the clinical workflow and real-time imaging capabilities of the InVue™ platform. During surgeries, the device will collect in vivo imaging data of the surgical cavity immediately after tumor removal to determine the clearance of the tumor in real-time. 

"This study represents a significant step in demonstrating the value InVue™ can deliver in managing and treating breast cancer. By delivering real-time, detailed cellular imaging directly in the operating theatre, we can empower surgeons with immediate, actionable insights to significantly improve the management and treatment of breast cancer,” Dr. Camile Farah, Optiscan CEO and Managing Director.

The study will recruit 50 patients undergoing breast conserving cancer surgery “lumpectomy” procedures at the Royal Melbourne Hospital, Frances Perry House and Epworth Hospital. 

This represents another significant step forward in our mission to revolutionize precision surgery and improve patient outcomes.

Read the full announcement here.